{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:20:22Z","timestamp":1787714422112,"version":"build-2784847793"},"reference-count":23,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Womens Health (Lond Engl)"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Danazol is a synthetic progestin with androgenic effects that is approved by the Food and Drug Administration for treatment of endometriosis, benign fibrocystic breast disease, and hereditary angioedema. In recent years, increasing numbers of transgender and nonbinary individuals seeking menstrual suppression have been offered danazol due to its potential to both induce amenorrhea and cause reversible androgenic side effects including pigmentation of vellus hairs and voice changes, which may be desirable in this population. There are currently no studies assessing use of danazol within the transgender population for menstrual suppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study\u2019s primary aim was to evaluate the use of danazol as a menstrual suppression agent in transgender patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This was a retrospective multisite cohort study of all individuals who had been on danazol at two tertiary care centers between 2000 and 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>All patients prescribed danazol were identified using a search of the electronic medical records. For demographic purposes, comparisons were made between those who did and did not use danazol for the purpose of menstrual suppression. A detailed chart review was then performed to analyze the experiences of menstrual suppression in transgender and nonbinary patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Most transgender and nonbinary patients on danazol for menstrual suppression remained on it at their most recent follow-up visit, and many charts noted improvements in gender dysphoria, pelvic pain, dysmenorrhea, endometriosis, and heavy menstrual bleeding. Most transgender patients achieved amenorrhea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Danazol may be a reasonable option for menstrual suppression in transgender and nonbinary patients. Our findings show its potential to not only induce amenorrhea but cause desired androgenic symptoms and improve gender dysphoria, pelvic pain, dysmenorrhea, endometriosis, and heavy bleeding. While the androgenic effects of danazol are less desirable in cisgender populations, it is an attractive option for menstrual suppression in transgender and nonbinary patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17455057241265081","type":"journal-article","created":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T07:55:54Z","timestamp":1721894154000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Danazol\u2019s use for menstrual suppression in transgender individuals: A retrospective multi-site cohort study"],"prefix":"10.1177","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-9283-1256","authenticated-orcid":false,"given":"Ava","family":"Scatoni","sequence":"first","affiliation":[{"name":"Division of Gynecology, Department of Surgery, Boston Children\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaine","family":"Roberts","sequence":"additional","affiliation":[{"name":"Division of Adolescent Medicine, Department of Pediatrics, Penn State Health Children\u2019s Hospital, Hershey, PA, USA"},{"name":"Department of Psychology, Penn State Harrisburg, Middletown, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4982-1323","authenticated-orcid":false,"given":"Elizabeth R","family":"Boskey","sequence":"additional","affiliation":[{"name":"Division of Gynecology, Department of Surgery, Boston Children\u2019s Hospital, Boston, MA, USA"},{"name":"Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Staffa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Boston Children\u2019s Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6665-1795","authenticated-orcid":false,"given":"Rosemary Claire","family":"Roden","sequence":"additional","affiliation":[{"name":"Division of Adolescent Medicine, Department of Pediatrics, Penn State Health Children\u2019s Hospital, Hershey, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emile","family":"Redwood","sequence":"additional","affiliation":[{"name":"Division of Gynecology, Department of Surgery, Boston Children\u2019s Hospital, Boston, MA, USA"},{"name":"Department of Obstetrics & Gynecology, New York University Langone Long Island School of Medicine, Mineola, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2442-724X","authenticated-orcid":false,"given":"Frances","family":"Grimstad","sequence":"additional","affiliation":[{"name":"Division of Gynecology, Department of Surgery, Boston Children\u2019s Hospital, Boston, MA, USA"},{"name":"Department of Obstetrics, Gynecology, and Reproductive Biology, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,7,25]]},"reference":[{"key":"bibr1-17455057241265081","unstructured":"Danazol, https:\/\/pubmed.ncbi.nlm.nih.gov\/7041729\/ (accessed 29 February 2024)."},{"key":"bibr2-17455057241265081","unstructured":"US Food and Drug Administration (FDA). Danocrine brand of danazol capsules, USP prescribing information. Silver Spring, MD: FDA, 2013, pp. 1\u20139."},{"key":"bibr3-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)37981-X"},{"key":"bibr4-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13184"},{"key":"bibr5-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2018.1435045"},{"key":"bibr6-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1016\/S0015-0282(16)54718-9"},{"key":"bibr7-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(91)90547-5"},{"key":"bibr8-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1097\/00003081-199112000-00022"},{"key":"bibr9-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1177\/26334941231158251"},{"key":"bibr10-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1080\/13691058.2016.1182645"},{"key":"bibr11-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003308"},{"key":"bibr12-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpag.2016.01.100"},{"key":"bibr13-17455057241265081","unstructured":"General approaches to medical management of menstrual suppression, https:\/\/www.acog.org\/clinical\/clinical-guidance\/clinical-consensus\/articles\/2022\/09\/general-approaches-to-medical-management-of-menstrual-suppression (accessed 26 February 2024)."},{"key":"bibr14-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpag.2021.04.004"},{"key":"bibr15-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005317"},{"key":"bibr16-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008475"},{"key":"bibr17-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1111\/jmwh.13310"},{"key":"bibr18-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpag.2022.10.007"},{"key":"bibr19-17455057241265081","unstructured":"Ashfaq S, Pellegrini MV, Can AS. Danazol. In: StatPearls. Treasure Island, FL: StatPearls Publishing, 2024, http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564344\/ (accessed 26 February 2024)."},{"key":"bibr20-17455057241265081","doi-asserted-by":"publisher","DOI":"10.21037\/tau.2016.09.04"},{"key":"bibr21-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1007\/s10508-021-02178-3"},{"key":"bibr22-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2023-062202"},{"key":"bibr23-17455057241265081","doi-asserted-by":"publisher","DOI":"10.1080\/26895269.2022.2100644"}],"container-title":["Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17455057241265081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17455057241265081","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17455057241265081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T08:27:24Z","timestamp":1777710444000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17455057241265081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":23,"alternative-id":["10.1177\/17455057241265081"],"URL":"https:\/\/doi.org\/10.1177\/17455057241265081","relation":{},"ISSN":["1745-5057","1745-5065"],"issn-type":[{"value":"1745-5057","type":"print"},{"value":"1745-5065","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"17455057241265081"}}